Teva Q3 Profit Beats Estimates, Raises 2014 Forecast

Global sales of its best-selling multiple sclerosis drug Copaxone rose 5 percent to $1.1 billion.

Reuters
Reuters
Send in e-mailSend in e-mail
Send in e-mailSend in e-mail
Teva's headquarters in Jerusalem.
Teva's headquarters in Jerusalem.Credit: Bloomberg
Reuters
Reuters

REUTERS - Teva Pharmaceutical Industries reported quarterly profit that beat analysts' estimates on Thursday due to improved profitability for its generic medicines, and raised the lower end of its 2014 earnings forecast.

Teva, the world's largest generic drugmaker and Israel's biggest company, earned $1.32 per diluted share excluding one-time items in the third quarter, compared with $1.27 a year earlier. Revenue was unchanged at $5.1 billion.

Teva was forecast to earn $1.24 a share excluding items on revenue of $5.1, according to Thomson Reuters I/B/E/S.

"We delivered improvement in profitability in all businesses, particularly in global generics, which saw profitability increase by 40 percent year over year," Chief Executive Erez Vigodman said, adding that the company was committed to executing its cost reduction program.

Global sales of its best-selling multiple sclerosis drug Copaxone, which accounts for about 20 percent of sales and 50 percent of profit, rose 5 percent to $1.1 billion. The injectable drug faces competition from oral treatments as well as cheaper generics in coming years.

Teva raised its outlook for full-year earnings per share excluding one-time items to $5.00-$5.10 from a previous estimate of $4.90-$5.10, assuming there is no Copaxone competition this year. It sees revenue of $20-$20.3 billion, compared with a previous estimate of $19.9-$20.8 billion.

Analysts were estimating Teva would earn $4.97 a share.

It said the introduction of generic competition to Copaxone could reduce operating income by $40-$50 million per month.

"Our pipeline is poised to deliver significant long-term value and we will continue the efforts to further deepen and develop it. We are well positioned to achieve our goals for 2014," Vigodman said.

Teva increased its share repurchase program by $1.7 billion to $3 billion with purchases to begin promptly.

It declared a quarterly dividend of 1.21 shekels (32 cents) a share, unchanged from the second quarter.

Comments

SUBSCRIBERS JOIN THE CONVERSATION FASTER

Automatic approval of subscriber comments.

Subscribe today and save 40%

SUBSCRIBE
Already signed up? LOG IN

ICYMI

Trump and Netanyahu at the White House in Washington, in 2020.

Three Years Later, Israelis Find Out What Trump Really Thought of Netanyahu

German soldier.

The Rival Jewish Spies Who Almost Changed the Course of WWII

Rio. Not all Jewish men wear black hats.

What Does a Jew Look Like? The Brits Don't Seem to Know

Galon. “I’m coming to accomplish a specific mission: to increase Meretz’s strength and ensure that the party will not tread water around the electoral threshold. If Meretz will be large enough, it will be the basis for a Jewish-Arab partnership.” Daniel Tchetchik

'I Have No Illusions About Ending the Occupation, but the Government Needs the Left'

Soldiers using warfare devices made by the Israeli defense electronics company Elbit Systems.

Russia-Ukraine War Catapults Israeli Arms Industry to Global Stage

Flame and smoke rise during an Israeli air strike, amid Israel-Gaza fighting, in Gaza City August 6, 2022.

Israel Should End Gaza Operation Now, if It Can